Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Association Between Metabolic Syndrome, Obesity, and Cognitive Performances in Individuals With Bipolar Disorders: Cross‐Sectional and Longitudinal Analyses in the FACE ‐ BD Cohort

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Fondation FondaMental Créteil; IMRB - "Neuropsychiatrie translationnelle" Créteil (U955 Inserm - UPEC); Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S 1144 / U1144)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); GHU AP-HP Nord - Université Paris Cité; Hôpital Lariboisière-Fernand-Widal APHP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Hôpital Henri Mondor; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine Créteil, France (FHU ADAPT); Service NEUROSPIN (NEUROSPIN); Université Paris-Saclay-Institut des Sciences du Vivant Frédéric JOLIOT (JOLIOT); Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA); Centre hospitalier Charles Perrens Bordeaux; Hôpital Princesse Grace Monaco; Institut de Génomique Fonctionnelle (IGF); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM); Département de Psychiatrie adulte Hôpital de la Colombière - CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Hôpital la Colombière CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Hôpital Louis Mourier - AP-HP Colombes; Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm); Centre d'Investigation Clinique de Besançon (Inserm CIC 1431); Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang Bourgogne-Franche-Comté (EFS BFC)-Université de Franche-Comté (UFC); Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC); Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO); Université de Franche-Comté (UFC); Institut de Neurosciences de la Timone (INT); Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS); Département Universitaire de Psychiatrie - Hôpital Sainte Marguerite - APHM (Hôpitaux Sud); Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite CHU - APHM (Hôpitaux Sud); Service Psychiatrie Adulte CHU Clermont-Ferrand; CHU Gabriel Montpied Clermont-Ferrand; CHU Clermont-Ferrand-CHU Clermont-Ferrand-Pôle Psychiatrie Enfant-Adulte CHU Clermont-Ferrand; CHU Clermont-Ferrand-CHU Gabriel Montpied Clermont-Ferrand; CHU Clermont-Ferrand; Institut Pascal (IP); Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne); Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA); Centre Hospitalier Universitaire CHU Grenoble (CHUGA); GIN Grenoble Institut des Neurosciences (GIN); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA); Centre Psychothérapique de Nancy Laxou (CPN); Imagerie Adaptative Diagnostique et Interventionnelle (IADI); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL); Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse; AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Centre Hospitalier de Versailles André Mignot (CHV); ANR-11-IDEX-0004,SUPER,Sorbonne Universités à Paris pour l'Enseignement et la Recherche(2011); ANR-10-COHO-0010,Psy-COH,FondaMental-Cohortes(2010)
    • Publication Information:
      CCSD
      Wiley
    • Publication Date:
      2026
    • Abstract:
      International audience ; Introduction: Metabolic syndrome (MetS) has been suggested to be associated with cognitive impairments in bipolar disorder (BD); however, studies are limited by small sample sizes or cross-sectional design. Our objective is to evaluate the cross-sectional and longitudinal associations between MetS and cognitive performances in a large cohort of individuals with BD.Methods: 1175 individuals with a DSM-IV diagnosis of BD were included from the FACE-BD cohort, assessed with a standardized battery of clinical and neuropsychological tests and followed up with a cognitive retest at 2 years for a subsample (n = 367). A global cognitive index was created by using a Principal Component Analysis. Associations between MetS and cognitive performances at baseline were explored using multiple analyses of covariance and linear mixed models were used for longitudinal data.Results: The prevalence of MetS was 21.5% in this sample. Multivariable analyses identified associations between MetS and poorer cognitive performance in the cross-sectional analysis, independently of age, gender, education level, psychotropic treatments, and comorbidities. Specifically, individuals with MetS showed poorer results (global cognitive index, cognitive flexibility, inhibition, and verbal memory). After adjustment, the longitudinal analysis showed no change in the global cognitive index at year 2 and no time × metabolic syndrome interaction.Conclusions: Our results suggest that MetS is cross-sectionally, but not longitudinally, associated with poorer cognitive performances in BD. This study highlights the importance of systematically and accurately screening for metabolic abnormalities in individuals with BD, and screening for cognitive deficit especially in individuals with MetS. Our results suggest that MetS is not a risk factor for cognitive decline during the follow-up, but further longitudinal studies are required.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/41265904; PUBMED: 41265904; PUBMEDCENTRAL: PMC12779237
    • Accession Number:
      10.1111/acps.70048
    • Online Access:
      https://hal.science/hal-05384115
      https://hal.science/hal-05384115v1/document
      https://hal.science/hal-05384115v1/file/Palimaru%20et%20al%202025.pdf
      https://doi.org/10.1111/acps.70048
    • Rights:
      https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.132F6670